Country	Research & Innovation	Coordination &	Training	Strategic	Other	Total 2023
		Support		Partnership		
				Building		
Austria		750.000,0€				750.000,0€
Belgium	1.800.000,0€	950.000,0€				2.750.000,0€
Ethiopia	200.000,0€					200.000,0 €
France	4.203.000,0€	20.160.000,0€	3.140.000,0€	630.000,0€	520.000,0€	28.653.000,0€
Germany				2.000.000,0€		2.000.000,0€
Mali	321.715,8€					321.715,8€
Mozambique				100.000,0€		100.000,0 €
Norway	300.000,0€					300.000,0 €
Portugal	370.000,0€		70.000,0€			440.000,0€
South Africa	1.697.000,0€		293.785,0€			1.990.785,0 €
Spain	1.413.000,0€					1.413.000,0 €
Uganda	12.674.011,0€					12.674.011,0€
United Kingdom	32.128.702,0€		2.900.000,0€			35.028.702,0 €
Total 2023	55.107.428,8 €	21.860.000,0 €	6.403.785,0 €	2.730.000,0 €	520.000,0 €	86.621.213,8 €

GH EDCTP3 ANNUAL WORK PROGRAMME IN KIND CONTRIBUTIONS TO ADDITIONAL ACTIVITIES TO BE INITIATED IN 2023

			GH EDCTP3 AN	NUAL WORK PROGRAM	MME IN F	CIND CONTRIBU	TIONS TO ADDITIC	ONAL ACTIVITIES	S TO BE INITIATED IN	N 2023				
Number	GH EDCTP3 Participating Stat	e Title	Short description	Funding organisation	Duration (months)	sub-Saharan Africa countries involved	Keywords	Type of Activity	Comments	Co-funding	Contribution to GH EDCTP3 specific objectives	Contribution to Horizon Europe operational objectives	Planned task to link with other EDCTP Member State Additional Activity	Estimate commitm (€)
IKAA2023-3393	Austria	Capacity Building for poverty- related infectious diseases in Sub- Saharan Africa	clinical and biomedical research facilities, including research training. The aim ist to establish high-quality clinical and biomedical research for etiology, epidemiology, diagnosis, drug and vaccine development, with regard to all infectious diseases	Austrian Federal Ministry of Education, Science and Research	99	Gabon	Capacity development	Coordination & Support activity	1 1		Strengthen research and innovation capacity	Strengthen international cooperation	Meetings with one or more other EDCTP Member States active in capacity building will take place, to find synergies with other GH EDCTP3 Member States Activities.	<u>I</u> €7
IKAA2023-3429	Belgium	WHO TDR	Belgian financial support to WHO TDR for research for policy, implementation, innovation and integrated approaches.	Belgian Development Cooperation - DGD	24	TBC	Operational research; Implementation research; Capacity development; HIV; Echinococcosis; Foodborne trematodiases; Lymphatic filariasis; Onchocerciasis (river blindness); Schistosomiasis Buruli ulcer; Soil- transmitted helminthiases; Leprosy (Hansen disease); Trachoma; Yaws; Diarrhoeal diseases; Malaria; Lower respiratory infections; Emerging infections, incl. Ebola, Lassa Fever; Mycetoma; Yellow Fever; Co-infections; Tuberculosis; Dengue/Severe Dengue; Rabies; Human African trypanosomiasis (sleeping sickness); Leishmaniases; Cysticercosis/Taeniasis; Dracunculiasis (guinea- worm disease); COVID-19	activity ;;	n The work of TDR is of relevance for all countries in SSA, therefore no countries have been specified.		Strengthen research and innovation capacity	Support scientific evidence based implementation of policies	Other EDCTP member states like Sweden, Germany, Norway, Spain and UK are core donors of TDR. EDCTP has programmatic collaboration with TDR. It is planned to continue regular dialogue.	€ 1.2
IKAA2023-3428	Belgium	Strengthening Provincial Health Services Tete Mozambique	Support to the Provincial Health Service in Tete Province Mozambique and through funding technical support by the Institute of Tropical Medicine in Antwerp. Support is given to Health System Strengthening: monitoring of key health indicators, action research on most precarious indicators, support to infrastructure. Training and education of health	Flanders Chancellery and Foreign Affairs	36	Mozambique	Maternal and child health; Capacity development; Health systems	Coordination & Support activity			Promote networking, building partnerships and strategic alliances	Strengthen international cooperation	Invitation of beneficiaries to ITM's annual Joint Partner Meeting, for exchange and exploring synergy with 24 other institutional global partners of ITM on research and capacity building.	€ 9
IKAA2023-3427	Belgium	ITM competitive research program	Supporting research proposals with potential to push knowledge boundaries and its applications, aligning with ITM's mission to progress science in tropical medicine and public health. Projects are conducted in global partnerships incl. academia in SSA and fit with ITM research priorities on emerging diseases, AMR, disease elimination, sustainable health systems.	Flemish Ministry of Economy, Sciences and Innovation	24	TBC	Maternal and child health; Epidemiology; Social science; Health systems; HIV; Schistosomiasis; Leprosy (Hansen disease); Malaria; Emerging infections, incl. Ebola, Lassa Fever; Tuberculosis; Dengue/Severe Dengue; Rabies; Human African trypanosomiasis (sleeping sickness); Leishmaniases	activity	Involved SSA countries are N not known yet as research proposals were still under evaluation at time of IKAA submission, projects will be awarded in the fall of 2022 and activities will start in 2023.		Advance development an use of new or improved technologies	d Spread excellence	Workshops between recipients and feedback discussions with European funding institutions/ networks (eg. ALERRT, PANDORA,JPI-AMR,) including GH EDCTP3 Member States representatives to find synergies.	€ 6
IKAA2023-3437	Ethiopia	In-kind contribution from Ethiopia	Ethiopia is member of the General Assembly of EDCTP would like to contribute in-kind to the global research collaboration. Armauer Hansen Research Institute is a public biomedical and clinical research institute operating under ministry of health. The research undertakings supported by our institutes can be considered as in IKAA	Ethiopian Public Health Institute	12	Ethiopia		Research & Innovation activity	 n 1. On the publication of post graduate students EDCTP will be acknowledged 2. The conference will be organized in collaboration with Norway and will take place in Addis Ababa 	Norad, Norway	Strengthen research and innovation capacity	Strengthen scientific excellence	We support PhD and Masters students to conduct medical research. We will organize Health and Education conference involving other EDCTP Member States to find synergies with other GH EDCTP3 IKAAs. We nurture health innovations through Grand Challenges Ethiopia funding mechanism.	

			GH EDCTP3 AN	INUAL WORK PROGRAM	MME IN K	(IND CONTRIBL	JTIONS TO ADDITIC	ONAL ACTIVITIES	S TO BE INITIATED II	N 2023				
Number	GH EDCTP3 Participating Stat	e Title	Short description	Funding organisation	Duration (months)	sub-Saharan Africa countries involved	Keywords	Type of Activity	Comments	Co-funding	Contribution to GH EDCTP3 specific objectives	Contribution to Horizon Europe operational objectives	Planned task to link with other EDCTP Member State Additional Activity	Estimato commitm (€)
IKAA2023-3393	Austria	Capacity Building for poverty- related infectious diseases in Sub- Saharan Africa	research training. The aim ist to establish high-quality clinical and biomedical research for etiology, epidemiology, diagnosis, drug and vaccine development, with regard to all infectious diseases	Austrian Federal Ministry of Education, Science and Research	99	Gabon	Capacity development	Coordination & Support activity			Strengthen research and innovation capacity	Strengthen international cooperation	Meetings with one or more other EDCTP Member States active in capacity building will take place, to find synergies with other GH EDCTP3 Member States Activities.	€ 7
IKAA2023-3429	Belgium	WHO TDR	Belgian financial support to WHO TDR for research for policy, implementation, innovation and integrated approaches.	Belgian Development Cooperation - DGD	24	TBC	Operational research; Implementation research; Capacity development; HIV; Echinococcosis; Foodborne trematodiases; Lymphatic filariasis; Onchocerciasis (river blindness); Schistosomiasis Buruli ulcer; Soil- transmitted helminthiases; Leprosy (Hansen disease); Trachoma; Yaws; Diarrhoeal diseases; Malaria; Lower respiratory infections; Emerging infections, incl. Ebola, Lassa Fever; Mycetoma; Yellow Fever; Co-infections; Tuberculosis; Dengue/Severe Dengue; Rabies; Human African trypanosomiasis (sleeping sickness); Leishmaniases; Cysticercosis/Taeniasis; Dracunculiasis (guinea- worm disease); COVID-19	activity ;;	n The work of TDR is of relevance for all countries in SSA, therefore no countries have been specified.		Strengthen research and innovation capacity	Support scientific evidence based implementation of policies	Other EDCTP member states like Sweden, Germany, Norway, Spain and UK are core donors of TDR. EDCTP has programmatic collaboration with TDR. It is planned to continue regular dialogue.	€ 1.2
IKAA2023-3428	Belgium	Strengthening Provincial Health Services Tete Mozambique	Support to the Provincial Health Service in Tete Province Mozambique and through funding technical support by the Institute of Tropical Medicine in Antwerp. Support is given to Health System Strengthening: monitoring of key health indicators, action research on most precarious indicators, support to infrastructure. Training and education of health	Flanders Chancellery and Foreign Affairs	36	Mozambique	Maternal and child health; Capacity development; Health systems	Coordination & Support activity			Promote networking, building partnerships and strategic alliances	Strengthen international cooperation	Invitation of beneficiaries to ITM's annual Joint Partner Meeting, for exchange and exploring synergy with 24 other institutional global partners of ITM on research and capacity building.	€ 9
IKAA2023-3427	Belgium	ITM competitive research program	Supporting research proposals with potential to push knowledge boundaries and its applications, aligning with ITM's mission to progress science in tropical medicine and public health. Projects are conducted in global partnerships incl. academia in SSA and fit with ITM research priorities on emerging diseases, AMR, disease elimination, sustainable health systems.	Flemish Ministry of Economy, Sciences and Innovation	24	TBC	Maternal and child health; Epidemiology; Social science; Health systems; HIV; Schistosomiasis; Leprosy (Hansen disease); Malaria; Emerging infections, incl. Ebola, Lassa Fever; Tuberculosis; Dengue/Severe Dengue; Rabies; Human African trypanosomiasis (sleeping sickness); Leishmaniases	activity	n Involved SSA countries are I not known yet as research proposals were still under evaluation at time of IKAA submission, projects will be awarded in the fall of 2022 and activities will start in 2023.	NA	Advance development an use of new or improved technologies	d Spread excellence	Workshops between recipients and feedback discussions with European funding institutions/ networks (eg. ALERRT, PANDORA,JPI-AMR,) including GH EDCTP3 Member States representatives to find synergies.	€ 6
IKAA2023-3437	Ethiopia	In-kind contribution from Ethiopia	Ethiopia is member of the General Assembly of EDCTP would like to contribute in-kind to the global research collaboration. Armauer Hansen Research Institute is a public biomedical and clinical research institute operating under ministry of health. The research undertakings supported by our institutes can be considered as in IKAA	Ethiopian Public Health Institute	12	Ethiopia		Research & Innovation activity	 n 1. On the publication of I post graduate students EDCTP will be acknowledged 2. The conference will be organized in collaboration with Norway and will take place in Addis Ababa 	Norad, Norway	Strengthen research and innovation capacity	Strengthen scientific excellence	We support PhD and Masters students to conduct medical research. We will organize Health and Education conference involving other EDCTP Member States to find synergies with other GH EDCTP3 IKAAs. We nurture health innovations through Grand Challenges Ethiopia funding mechanism.	€ 2

r	- 1	1	GH EDCTP3 AN	INUAL WORK PROGRAM	MME IN F		JTIONS TO ADDITIC		S TO BE INITIATED I	N 2023	T	1	-	
Number	GH EDCTP3 Participating State	e Title	Short description	Funding organisation	Duration (months)	sub-Saharan Africa countries involved	Keywords	Type of Activity	Comments	Co-funding	Contribution to GH EDCTP3 specific objectives	Contribution to Horizon Europe operational objectives	Planned task to link with other EDCTP Member State Additional Activity	Estimat commitm (€)
IKAA2023-3393	Austria	Capacity Building for poverty- related infectious diseases in Sub- Saharan Africa	research training. The aim ist to establish high-quality clinical and biomedical research for etiology, epidemiology, diagnosis, drug and vaccine development, with regard to all infectious diseases	Austrian Federal Ministry of Education, Science and Research	99	Gabon	Capacity development	Coordination & Support activity			Strengthen research and innovation capacity	Strengthen international cooperation	Meetings with one or more other EDCTP Member States active in capacity building will take place, to find synergies with other GH EDCTP3 Member States Activities.	€
IKAA2023-3429	Belgium	WHO TDR	Belgian financial support to WHO TDR for research for policy, implementation, innovation and integrated approaches.	Belgian Development Cooperation - DGD	24	TBC	Operational research; Implementation research; Capacity development; HIV; Echinococcosis; Foodborne trematodiases; Lymphatic filariasis; Onchocerciasis (river blindness); Schistosomiasis, Buruli ulcer; Soil- transmitted helminthiases; Leprosy (Hansen disease); Trachoma; Yaws; Diarrhoeal diseases; Malaria; Lower respiratory infections; Emerging infections, incl. Ebola, Lassa Fever; Mycetoma; Yellow Fever; Co-infections; Tuberculosis; Dengue/Severe Dengue; Rabies; Human African trypanosomiasis (sleeping sickness); Leishmaniases; Cysticercosis/Taeniasis; Dracunculiasis (guinea- worm disease); COVID-19	activity ;;	n The work of TDR is of relevance for all countries in SSA, therefore no countries have been specified.		Strengthen research and innovation capacity	Support scientific evidence based implementation of policies	Other EDCTP member states like Sweden, Germany, Norway, Spain and UK are core donors of TDR. EDCTP has programmatic collaboration with TDR. It is planned to continue regular dialogue.	€ 1.
IKAA2023-3428	Belgium	Strengthening Provincial Health Services Tete Mozambique	Support to the Provincial Health Service in Tete Province Mozambique and through funding technical support by the Institute of Tropical Medicine in Antwerp. Support is given to Health System Strengthening: monitoring of key health indicators, action research on most precarious indicators, support to infrastructure. Training and education of health	Flanders Chancellery and Foreign Affairs	36	Mozambique	Maternal and child health; Capacity development; Health systems	Coordination & Support activity			Promote networking, building partnerships and strategic alliances	Strengthen international cooperation	Invitation of beneficiaries to ITM's annual Joint Partner Meeting, for exchange and exploring synergy with 24 other institutional global partners of ITM on research and capacity building.	€
IKAA2023-3427	Belgium	ITM competitive research program	Supporting research proposals with potential to push knowledge boundaries and its applications, aligning with ITM's mission to progress science in tropical medicine and public health. Projects are conducted in global partnerships incl. academia in SSA and fit with ITM research priorities on emerging diseases, AMR, disease elimination, sustainable health systems.	Flemish Ministry of Economy, Sciences and Innovation	24	TBC	Maternal and child health; Epidemiology; Social science; Health systems; HIV; Schistosomiasis; Leprosy (Hansen disease); Malaria; Emerging infections, incl. Ebola, Lassa Fever; Tuberculosis; Dengue/Severe Dengue; Rabies; Human African trypanosomiasis (sleeping sickness); Leishmaniases	activity	Involved SSA countries are not known yet as research proposals were still under evaluation at time of IKAA submission, projects will be awarded in the fall of 2022 and activities will start in 2023.	NA	Advance development an use of new or improved technologies	d Spread excellence	Workshops between recipients and feedback discussions with European funding institutions/ networks (eg. ALERRT, PANDORA,JPI-AMR,) including GH EDCTP3 Member States representatives to find synergies.	€
IKAA2023-3437	Ethiopia	In-kind contribution from Ethiopia	Ethiopia is member of the General Assembly of EDCTP would like to contribute in-kind to the global research collaboration. Armauer Hansen Research Institute is a public biomedical and clinical research institute operating under ministry of health. The research undertakings supported by our institutes can be considered as in IKAA	Ethiopian Public Health Institute	12	Ethiopia		Research & Innovation activity	 1. On the publication of post graduate students EDCTP will be acknowledged 2. The conference will be organized in collaboration with Norway and will take place in Addis Ababa 	Norad, Norway	Strengthen research and innovation capacity	Strengthen scientific excellence	We support PhD and Masters students to conduct medical research. We will organize Health and Education conference involving other EDCTP Member States to find synergies with other GH EDCTP3 IKAAs. We nurture health innovations through Grand Challenges Ethiopia funding mechanism.	



1.200.000

950.000

600.000

200.000

2

IKAA2023-3418	France	Maintaining and strenghtening Infrastructure of BSL3 in Bamako	Ensure that the Laboratory of Rodolphe Mérieux (BSL3 Fondation Mérieux laboratory) at the Institute of Charles Mérieux in Bamako status remains at the required level of quality and standards (built by Fondation Mérieux for the benefit of Ministry of Health of Mali) .	72	Mali		Other			Strengthen capacity for epidemics preparedness	Increase collaboration across sectors	 Workshop between recipients € and feedback discussions between european funding institutions and networks (e.g. GloPID-R) including EDCTP3 MS representatives to find synergies between EDCTP3 MS ikaas
IKAA2023-3417	France	, ,	Creation of a new Medical Research Center dedicated Fondation Mérieux to maternal and child health for the Congolese Foundation	24	Congo, The Democratic Republic of the	Maternal and child health; Nursing	Other			Advance development and use of new or improved technologies	d Increase collaboration across sectors	Demonstration of the services € provided by the Medical Research Center dedicated to maternity (women and child) incl. infectious diseases. Open inauguration to present the new maternity and its services, to which other EDCTP Member States will be involved to find synergies with other GH EDCTP3 IKAAs.
IKAA2023-3416	France	DRC	Reinforce the high-security testing capacity (biosafety 2 Fondation Mérieux and 3 – belonging to the National Institute of Biomedical Research (INRB) in Goma) for surveillance and control of infectious disease outbreaks with epidemic potential of the Rodolphe Mérieux Laboratory based in DRC	12	Congo, The Democratic Republic of the		Other		USAID	Strengthen capacity for epidemics preparedness	Spread excellence	Workshop between recipients € and feedback discussions between european funding institutions and networks (e.g. GloPID-R) including EDCTP3 MS representatives to find synergies between EDCTP3 MS ikaaq.
IKAA2023-3415	France	Assessment of the clinical value of a POC syndromic Diagnostics	Evaluate the POC syndromic diagnostics with Meningitis/Encephalitis/Respiratory testing at bedside in children under 5 years of age in Burkina Faso, Cameroon, and Cote d'Ivoire compared to Standards of Care alone to reduce mortality and morbidity. Strengthen local diagnostics and clinical capacity at hospital level	24	Burkina Faso, Cameroon, Cote d'Ivoire		Research & Innovation activity		bioMérieux	Advance development and use of new or improved technologies	d Encourage exploitation of R&I results	Workshops between€recipients and feedbackdiscussions betweeneuropean funding institutionsand networks (e.g. GloPID-R)including EDCTP3 MStates tofind synergies betweenEDCTP3 Member States ikaas.
IKAA2023-3414	France	GABRIEL network	Strengthen research and training capacities of LMIC Fondation Mérieux laboratories and improve disease surveillance for major public health impact. Promote collaborations in infectious diseases and support local responses to health challenges, using collaborative research, tech transfer, training and knowledge sharing among 21	72	5	Capacity development; Emerging infections, incl. Ebola, Lassa Fever; Tuberculosis	Strategic Partnership Building activity			Promote networking, building partnerships and strategic alliances	Strengthen international cooperation	Short exchange of fellows€with another GH EDCTP3Member State additional activity to find synergies between GH EDCTP3 MemberStates additional activities.
IKAA2023-3413	France	MEPHI Activities	MEPHI's activities are multidisciplinary and transversalInstitut de Recherche pour le(epidemiological surveillance surveillance, clinicalDéveloppementresearch, microbiology, biostatistics, medicalinformation system information system)	36	Congo, Congo, The Democratic Republic of the, Gabon	Emerging infections, incl. Ebola, Lassa Fever	,	Non-human primates: roles in the emergence and re-emergence of zoonotic diseases in		Strengthen research and innovation capacity	Strengthen international cooperation	Short exchange of Member € IRD with another GH EDCTP3 Member State to find synergies between GH
IKAA2023-3412	France	CEPED Activities	The specificity of the unit is to work on the Institut de Recherche pour le transformations triggered by the globalisation process that affect the societies of the South, as well as the social practices and knowledge of their populations and social groups, particularly in the field of health.	36	Cote d'Ivoire, Zambia	Implementation research	Research & Innovation activity	Collaborative project for promoting implementation of research results into policy and practice		Strengthen research and innovation capacity	Strengthen international cooperation	EDCTP3 additional activities Short exchange of Member € IRD with another GH EDCTP3 Member State to find synergies between GH EDCTP3 additional activities.
IKAA2023-3411	France	UVE Activities	The surveillance of emerging viral pathologies includes Institut de Recherche pour le virological and environmental aspects as well as human sciences, epidemiology, modelling and public health. The main pathogens studied are arboviruses and	24	Cameroon, Central African Republic, Congo, The Democratic Republic of the Gabon	Malaria;Emerging infections, incl. Ebola, Lassa Fever	Research & Innovation a activity			Promote networking, building partnerships and strategic alliances	Strengthen international cooperation	Short exchange of Member € IRD with another GH EDCTP3 Member State to find synergies between GH EDCTP3 additional activities
IKAA2023-3410	France	PHARMADEV Activities	The main mission of the PHARMADEV research unit is Institut de Recherche pour le to contribute to improving the health of populations. Développement Développement (malaria and leishmaniasis), cancer, and more particularly hepatocellular carcinoma (HCC) which is highly provalent in developing countries.	24		Implementation research	activity	Collaborative project for promoting implementation of research results into policy and practice		Promote networking, building partnerships and strategic alliances	Strengthen international cooperation	Short exchange of Member € IRD with another GH EDCTP3 Member State to find synergies between GH EDCTP3 additional activities.
IKAA2023-3409	France	GHIGS Activities	The objectives of the GHiGS team are to generate data Institut de Recherche pour le on diseases affecting countries in the South and to use Développement these results to design and evaluate innovative interventions at the individual and population level and contribute to the advancement of global health.	36	•	HIV; Emerging infections, incl. Ebola, Lassa Fever; Tuberculosis	Research & Innovation activity			Strengthen research and innovation capacity	Strengthen international cooperation	Short exchange of Member € IRD with another GH EDCTP3 Member State to find synergies between GH EDCTP3 additional activities.
IKAA2023-3408	France	SESSTIM Activites	SESSTIM's researchers are developing research work to address current issues for society and its populations. Our work focuses mainly on cancer and infectious and transmissible diseases and targets populations in France, but also in the South, in the Mediterranean basin or in sub-Sabaran Africa	36	Burkina Faso, Gambia	HIV; Tuberculosis	Research & Innovation activity			Strengthen research and innovation capacity	Strengthen international cooperation	 Short exchange of Member € IRD with another GH EDCTP3 Member State to find synergies between GH EDCTP3 additional activities.

150.000

300.000

70.000

50.000

630.000

177.000

100.000

50.000

50.000

76.000

IKAA2023-3407	France	IRD Call 2022 -Young Teams Associated with IRD	5	Institut de Recherche pour le Développement	36	TBC	Malaria; Emerging infections, incl. Ebola, Lassa Fever	Coordination & Support activity		Strengthen research and innovation capacity	Strengthen international cooperation	Short exchange of Member € IRD with another GH EDCTP3 Member State to find synergies between GH
IKAA2023-3406	France	IRD Call 2022 - International Research Network	IRN - To build cooperation between partners and to stimulate the exchange of ideas, energies and resources to address the challenges posed by falciparum malaria in the West African sub-region	Institut de Recherche pour le Développement	60	ТВС	Malaria; Negleted Infectious Diseases	Coordination & Support activity		Promote networking, building partnerships and strategic alliances	Strengthen international cooperation	FDCTP3 additional activities Short exchange of Member € IRD with another GH EDCTP3 Member State to find synergies between GH
IKAA2023-3405	France	IRD DAM 2023 - Funding of a doctoral thesis	ARTS - capacity building programme in southern countries to promote the completion of doctoral theses and the scientific training of students from southern countries	Institut de Recherche pour le Développement	6	ТВС	HIV; Malaria; Tuberculosis; Negleted Infectious Diseases	Training activity		Strengthen research and innovation capacity	Strengthen international cooperation	FDCTP3 additional activities Short exchange of Member € IRD with another GH EDCTP3 Member State to find synergies between GH
IKAA2023-3404	France	Operational Research Call for proposal	Support to operational research projects on malaria	L'Initiatve/Expertise France	48	ТВС	Operational research; Malaria	Research & Innovation activity	n	Strengthen research and innovation capacity	Strengthen scientific excellence	EDCTP3 additional activities A teleconference with one or € more EDCTP Member State
IKAA2023-3403	France	Training Lab technicians	To train lab technicians of peripheral labs (mainly CBOs) in Niger	L'Initiatve/Expertise France	24	Niger	Lab training	Training activity	This project is led in close collaboration with the Niger Ministry of Health	Strengthen research and innovation capacity	Strengthen scientific excellence	A teleconference with one or € more EDCTP Member State
IKAA2023-3402	France	Field Epidemiologiy training (FELTP)	To build field epidemiology capacities in 10 west African countries, with a focus on One Health	L'Initiatve/Expertise France	36	ТВС	Epidemiology	Training activity	This project is roll out in partnership with ISPED-	Strengthen research and innovation capacity	Strengthen scientific excellence	A teleconference with one or € More EDCTP Member State
IKAA2023-3401	France	ANRS-EID HR support for LMIC Project coordination	To support the implementation and valorization of research in LMICs, and to encourage the emergence of synergies between research teams in the North and South, ANRS-EID finances research coordination positions with a national/regional scope.	ANRS Emerging Infectious Diseases (ANRS EID)	12	Senegal, Zambia	HIV; Emerging infections, incl. Ebola, Lassa Fever; Co- infections; Tuberculosis; COVID-19; Hepatitis, STI, Viral Hepatitis		Bordeaux	Strengthen research and innovation capacity	Reinforce links between R&I, edu, training & other policies	Discussions with African and European research teams and funders to present and synergize our efforts in LMICs in order to better align
IKAA2023-3400	France	ANRS-EID Special projects funded outside CFPs		ANRS Emerging Infectious Diseases (ANRS EID)	36	TBC	HIV; Emerging infections, incl. Ebola, Lassa Fever; Co- infections; COVID-19; Hepatitis, STI, Viral Hepatitis			Strengthen research and innovation capacity	Reinforce links between R&I, edu, training & other policies	Workshops between € recipients and feedback discussions between european funding institutions and networks (e.g. GloPID-R)
IKAA2023-3399	France	ANRS-EID Annual support for Partner Sites 2023	ANRS-EID has 10 Research Partner Sites worldwide, among which 6 in SSA. The sites are home to numerous research projects carried out by French and local teams. They liaise with local and international health authorities and partners. ANRS-EID supports them through annual funding.	ANRS Emerging Infectious Diseases (ANRS EID)	12	Burkina Faso, Cameroon, Congo, The Democratic Republic of the, Cote d'Ivoire, Guinea, Senegal	Epidemiology; Operational research; Social science; Capacity development; Health systems; HIV; Emerging infections, incl. Ebola, Lassa Fever; Co- infections; Tuberculosis; COVID-19	Coordination & Support activity		Strengthen research and innovation capacity	Reinforce links between R&I, edu, training & other policies	Workshops between € recipients and feedback discussions between european funding institutions and networks (e.g. GloPID-R)
IKAA2023-3398	France	ANRS-EID Ad Hoc CFP on EIDs 2023-2	The Ad Hoc CFP on EIDs aims to fund research on any emerging infectious disease that needs further support in LMICs, such as Ebola, Lassa fever, Marburg fever, etc, depending on the urgency and the needs expressed by local authorities.		48	TBC	Emerging infections, incl. Ebola, Lassa Fever;COVID- 19			Strengthen research and innovation capacity	Reinforce links between R&I, edu, training & other policies	Workshops between € recipients and feedback discussions between european funding institutions and networks (e.g. GloPID-R)
IKAA2023-3397	France	ANRS-EID Ad Hoc CFP on EIDs 2023-1	The Ad Hoc CFP on EIDs aims to fund research on any emerging infectious disease that needs further support in LMICs, such as Ebola, Lassa fever, Marburg fever, etc, depending on the urgency and the needs expressed by local authorities.	1 5 5	48	TBC	Emerging infections, incl. Ebola, Lassa Fever;COVID- 19			Strengthen research and innovation capacity	Reinforce links between R&I, edu, training & other policies	Workshops between € recipients and feedback discussions between european funding institutions and networks (e.g. GloPID-R)
IKAA2023-3396	France	ANRS-EID Annual Call for Proposals on EIDs 2023	•	ANRS Emerging Infectious Diseases (ANRS EID)	48	TBC	Emerging infections, incl. Ebola, Lassa Fever;COVID- 19			Strengthen research and innovation capacity	Reinforce links between R&I, edu, training & other policies	Workshops between € recipients and feedback discussions between european funding institutions and networks (e.g. GloPID-R)
IKAA2023-3395	France	ANRS-EID Annual Call for Proposals 2023-2	HIV, viral hepatitis, STIs, TB, and EIDs. It funds grant applications for clinical research, capacity building initiatives, PhD grants via the launch of 2 annual CFP	ANRS Emerging Infectious Diseases (ANRS EID)	48	TBC	HIV; Co-infections; Tuberculosis; Hepatitis, STI, Viral Hepatitis	Coordination & Support activity		Strengthen research and innovation capacity	Reinforce links between R&I, edu, training & other policies	Workshops between € recipients and feedback discussions between european funding institutions and networks (e.g. GloPID-R)
IKAA2023-3394	France	ANRS-EID Annual Call for Proposals 2023-1	(FIDs excluded) ANRS-EID is a Public Institution whose missions are to facilitate, evaluate, coordinate, and fund research into HIV, viral hepatitis, STIs, TB, and EIDs. It funds grant applications for clinical research, capacity building initiatives, PhD grants via the launch of 2 annual CFP (FIDs excluded)	ANRS Emerging Infectious Diseases (ANRS EID)	48	TBC	HIV; Co-infections; Tuberculosis; Hepatitis, STI, Viral Hepatitis	Coordination & Support activity		Strengthen research and innovation capacity	Reinforce links between R&I, edu, training & other policies	Workshops between € recipients and feedback discussions between european funding institutions and networks (e.g. GloPID-R)

100.000

60.000

140.000

3.600.000

300.000

2.700.000

2.000.000

1.200.000

1.800.000

3.000.000

3.000.000

3.000.000

3.000.000

3.000.000

IKAA2023-3420	Germany	JPIAMR Call 2023	JPIAMR coordinates member states' activities and national research funding on the topic of antibiotic resistance. Through joint, transnational funding initiatives, gaps between scientists and other stakeholders (e.g. industry, healthcare systems, politics) are to be closed in particular in order to generate new research results and to lead these into application.	German Federal Ministry of Education and Research	36	South Africa	Drugs	Strategic Partnership Building activity			Facilitate better alignment of countries around a common Strategic Research and Innovation Agenda	Strengthen international cooperation	The general coordination is done by the Management Board in which all member countries (such as Sweden, Spain, France, UK) are represented	€
IKAA2023-3440	Mali	Age-specific impact of seasonal malaria chemoprevention in Mali	This is a cohort study in an area where malaria transmission is sharply seasonal and where Seasonal malaria chemoprevention (SMC) has been implemented at scale using Amodiaquine-Sulfadoxine-Pyrimethamine combination therapies. The main aim is to assess the long-term impact of SMC on various malariometric indices	TBC	36	Mali	Malaria; Seasonal malaria chemoprevention; Age- specific malaria incidence	Research & Innovation activity		US National Institutes for Health (NIH/NIAID/DM D)	Advance development and use of new or improved technologies	d Strengthen scientific excellence	A workshop on changing epidemiology of malaria will be held with partners from Senegal and France	€
IKAA2023-3443	Mali	Human and bovine schistosomiasis hybridization in Mali	This study aims to assess the occurrence of hybridization between Schistosoma haematobium and S. bovis in an area where both are endemic respectively in the human and bovine populations. Cattle breeding is an important economic activity in the region of Kayes in Mali where	Government of Mali via the FCRIT (Fond Compétitif pour la Recherche et l'Innovation Scientifique)	24	Mali	Schistosomiasis; Epidemiology; Schistosomiasis hybridization	Research & Innovation activity			Advance development and use of new or improved technologies	d Spread excellence	Short exchange of fellows with partners in Benin	€
IKAA2023-3445	Mali	Association of Tuberculosis and Diabetes in Mali	This study aims to assess risk factors for tuberculosis in diabetes. A cohort of diabetic patients will be constituted across all Mali and followed for 2 years to determine the incidence and prevalence of TB and identify risk factors associated with the occurrence of TB in diabetic patients.	FCRIT (Fond Compétitif pour la Recherche et l'Innovation Scientifique)	36	Mali	Tuberculosis; Drugs; Epidemiology; Diabetes	Research & Innovation activity			Advance development and use of new or improved technologies	d Spread excellence	Workshops will be organized with beneficiaries from others IKAAs by others partnering states	
IKAA2023-3432	Mozambique	Biomedical Research in the Manhiça Health Research Center 2023	General Objective: Strengthern the capacities of health research in Mozambique as a tool to provide the National Health System and international partners with scientific evidence in decision making Specific Objective: Consolidate the Fundação Manhiça/Manhiça Health Research Centre as a Mozambican Institution of reference in Biomedical Research	Ministry of Health	12	TBC	Data management; Statistics; Operational research; Demography; Capacity development	Strategic Partnership Building activity	The Monistry of Health pays salaries of members of staff at the Centre since its establishment in 1996 through a Bilateral Agreement between the Governments of Mozambique and Spain.		Promote networking, building partnerships and strategic alliances	Strengthen international cooperation	Short exchange of fellows with another Member State The University of Barcelona in Spain will exchange fellows with the Manhiça Foundation vice versa.	
IKAA2023-3419	Norway	Ethics of post-trial arrangements in LLMICs during pandemics/epidemics	 Pandemic Ethics will develop country-based and global agendas for a just and practicable post-trial arrangements (PTA) for low and middle income countries (LMICs) during epidemic/pandemic situations. The project have partners from Kenya, Tanzania, India, the Philippines, Nepal, Brazil and Norway. 	The Research Council Of Norway	60	Kenya, Tanzania, United Republic of	Ethics; Regulatory affairs; Emerging infections, incl. Ebola, Lassa Fever; COVID- 19	activity	This project was recently funded by the RCN. We will soon start contract negotiations and the project will start i July 2023.		Advance development and use of new or improved technologies	d Strengthen scientific excellence	Workshop/meeting with stakeholders and GA representatives from the GH EDCTP3 Participating States Kenya, Tanzania and Norway.	€
IKAA2023-3431	Portugal	PhD Fellowships - Ciência LP	6 PhD Fellowships in Public Health for students with citizenship from Portuguese-speaking African countries or East Timor to perform research in Public Health in Portuguese Institutions in collaboration with institutions from Portuguese-speaking African countries or East Timor in themes of interest to these countries.		48	TBC		Research & Innovation activity			Strengthen research and innovation capacity	Reinforce links between R&I, edu, training & other policies	A workshop will be organised with beneficiaries from IKAAs funded by other GH EDCTP3 Participating States	
IKAA2023-3430	Portugal	lvermectin hybrids - potential insecticidal and multistage antiplasmodial drugs	The objective of this project is to characterize third- generation Ivermectin (IVM) hybrid molecules for maliaria control. This preclinical study will be crucial to establish IVM hybrids as potential antiplasmodial drugs and its use in the prevention and treatment of malaria.	Fundação para a Ciência e a Tecnologia	18	TBC		Research & Innovation activity			Advance development and use of new or improved technologies	d Strengthen scientific excellence	A workshop will be organised with beneficiaries from IKAAs funded by other GH EDCTP3 Participating States	
IKAA2023-3442	Portugal	FCT Call for PhD Research Studentships	The FCT Call for PhD Studentships supports researchers, in all areas of knowledge, who wish to develop research activities leading to a PhD degree. The work plan may be entirely or partially carried out in a national or foreign institution and is open to both national and foreign citizens.		48	TBC	Capacity development	Training activity			Strengthen research and innovation capacity	Strengthen scientific excellence	A workshop will be organised with beneficiaries from IKAAs funded by other GH EDCTP3 Participating States	
IKAA2023-3446	Portugal	FCT Individual Call to Scientific Employment Stimulus	The Individual Call is aimed at PhD holders of any nationality or stateless with a background in any scientific area who wish to develop their scientific research or technological development activity in	Fundação para a Ciência e a Tecnologia	72	ТВС		Research & Innovation activity			Strengthen research and innovation capacity	Strengthen scientific excellence	A workshop will be organised with beneficiaries from IKAAs funded by other GH EDCTP3 Participating States	
IKAA2023-3436	South Africa	TB Research – Capacity Development	Portugal Primary Objectives: Training MSc and PhD students in medicinal chemistry, drug discovery, organic synthesis, natural products research, and screening of compounds Presentation of the findings of the projects at local and international conferences	South African Medical Research Council	36	TBC		Training activity		N/A	Strengthen capacity for epidemics preparedness	Strengthen scientific excellence	A workshop will be organised with beneficiaries from IKAAs funded by other GH EDCTP3 Participating States	

2.000.000

17.080

152.219

152.417

100.000

300.000

120.000

50.000

70.000

200.000

IKAA2023-3435	South Africa	Phase 1 study - HIV-1 latent reservoir (NeutART)	Objectives: To determine whether monoclonal antibodies CAP256V2LS and VRC07-523LS, combined with ART affects the time to viral load rebound and time to ART reinitiation post ATI. To assess the safety of CAP256V2LS and VRC07-523LS administered IV to HIV positive participants before or at	South African Medical Research Council	36	TBC		Research & Innovation activity	N/A	N/A	Strengthen research and innovation capacity	Strengthen scientific excellence	A meeting will be organised with other GH EDCTP3 Participating States to find synergies between IKAAs	€
IKAA2023-3434	South Africa	TB Drug Discovery Hit to Lead Optimization	Primary objectives: Gain an understanding in rational drug design and development. Generate a library of new quinoxaline, pteridine, indole and benzofuran containing compounds which will be tested for the activity against Mtb as guided by the screening cascade and progression criteria employed at	South African Medical Research Council	36	TBC		Training activity		N/A	Strengthen capacity for epidemics preparedness	Encourage exploitation of R&I results	A meeting will be organised with other GH EDCTP3 Participating States to find synergies between IKAAs	€
IKAA2023-3433	South Africa	UMBRELLA 1 (SAMBULELO 1) TRIAL	HIV passive immunoprophylaxis to HIV infected and	South African Medical Research Council	36	ТВС		Research & Innovation activity		N/A	Strengthen research and innovation capacity	Strengthen scientific excellence	A meeting will be organised with other GH EDCTP3 Participating States to find	€
IKAA2023-3438	Spain	Equatorial Guinea: Support for health research capacities	breastfeeding HFU infants. Neglected Tropical Diseases present challenges associated with prevention and treatment and a negative impact on economic and social progress in LMIC. This IKKA aimed at transferring knowledge to EG biomedical research groups. Collaborative activities will be developed with the aim of facilitating training, prevention and control through application R&I evidence.	Spanish Agency of Cooperation for Development	36	Equatorial Guinea	Malaria; Onchocerciasis (river blindness); Drugs; Diagnostics; Capacity development; Health systems; Operational research; Implementation research	·	Main activity goal supporting national malaria and onchocerciasis programs in EG. Mapping resistance to antimalarials, and malaria prevalence and providing diagnostic support of human filariasis.	N/A	Strengthen research and innovation capacity	Strengthen international cooperation	svneraies between IKAAs ISCIII will promote and facilitate attendance of beneficiary researchers to next EDCTP III scientific forum in order to network with other researchers and stakeholder on the same research area	€
IKAA2023-3439	Spain	Mozambique: Health research capacity for evidence-based decisions	To build research capacity promoting scientific evidence translation into clinical practice to reduce the burden of infectious diseases in Mozambique. The specific objective of this Ikka is to consolidate the Fundación Manhiça Research Center as a Mozambican institution of reference in biomedical and public health research.		36	Mozambique	HIV; Malaria; Tuberculosis; Diarrhoeal diseases; Lower respiratory infections; Vaccines; Drugs; Diagnostics	activity	This activity conforms a continuous research ^o program which periodically incorporate new activities while others close. It is one of the Spanish public health research platforms in	Cataluña Goverment	Advance development and use of new or improved technologies	d Strengthen international cooperation	This IKKA is an activity open to the collaboration of participating states collaboration based on the EDCTPIII work plan for 2023 and beyond	€
IKAA2023-3451	Uganda	The 12th Annual National Research Ethics Conference (ANREC)	The 12th ANREC is a planned forum for the chairpersons of Institutional Ethics Committees and aims to create awareness and best practice in research and innovation to foster the capacity of the research centers in the region. The theme for the 12th ANREC will be community engagement	Government of Uganda	12	Uganda, Rwanda, Kenya, Malaria, Ethiopia, Namibia, Burundi	HIV; Malaria; COVID-19; Vaccines; Drugs; Regulatory affairs; Capacity development; Implementation research	Research & Innovation activity			Strengthen research and innovation capacity	Support scientific evidence based implementation of policies	Presentations from EDCTP funded research activities at the Makerere University collage of Health Sciences and Uganda National Health Research Organization/ Uganda Virus Research	€
IKAA2023-3452	Uganda	Makerere University Research and Innovation Fund	The Fund aims to build research capacity and promote individual and groups of young scientists that come up with excellent research ideas/proposals. The Fund aims to reinforce the link between research and innovation. The fund pairs experienced researchers with junior scientists		12	TBC	HIV; Malaria; Tuberculosis; Dengue/Severe Dengue; Leishmaniases; Co- infections; COVID-19; Ethics; Social science; Capacity development; Operational research; Implementation research	Research & Innovation activity			Advance development and use of new or improved technologies	d Spread excellence	Experienced researchers trained by EDCTP participate as mentors in this grant and many have won these grants	€
IKAA2023-3453	Uganda	Presidential Scientific Initiative on Epidemics	This funding for 3 on-going vaccine Trials on COVID-19 by Government of Uganda aimed to advance development and use of new or improved technologies	-	36	TBC	Vaccines; Diagnostics	Research & Innovation activity			Advance development and use of new or improved technologies	d Encourage exploitation of R&I results	Planned webinars and annual Meetings to share experiences through the Africa Research Hub	€
IKAA2023-3426	United Kingdom	African Research Leader (ARL) scheme 2023	Funding to support excellent global health research and strengthen research leadership across sub-Saharan Africa. The scheme aims to attract and retain exceptionally talented 'rising star' individuals who will lead high quality research on key global health issues pertinent to SSA.	l Foreign, Commonwealth & Development Office, Medical Research Council	60	TBC		Training activity			Advance development and use of new or improved technologies	excellence	Information exchanged with other GH EDCTP3 Member States in preparation for dialogue on partnership opportunities and to find synergies between GH EDCTP3 additional activities.	€
IKAA2023-3425	United Kingdom	MRC/UVRI and LSHTM Uganda Research Unit	The Unit's vision is "to contribute to the control of the HIV epidemic, of other infectious diseases, and of non- communicable diseases, in Uganda, the region and the world". It aims to deliver this via three themes: HIV & Emerging Infections, Vaccines & Immunity and Chronic Diseases & Cancer	Development Office, Medical	60	Uganda		Research & Innovation activity			Advance development and use of new or improved technologies	excellence	Information exchanged with other GH EDCTP3 Member States in preparation for dialogue on partnership opportunities and to find synergies between GH	€

840.000

144.600

857.000

288.000

1.125.000

213.076

7.989.321

4.471.614

1.740.000

18.374.400

6

IKAA2023-3424	United Kingdom	Applied Global Health Research 2023	The Applied Global Health Research Board supports applied research that will be of direct and primary benefit to the health of vulnerable populations living in LMICs to develop practical solutions to health challenges. This includes implementation research	Foreign, Commonwealth & Development Office, Medical Research Council	60	TBC		Research & Innovation activity			Advance development and Strengthen scientific use of new or improved excellence technologies	Information exchanged with other GH EDCTP3 Member States in preparation for dialogue on partnership opportunities and to find synergies between GH	
IKAA2023-3423	United Kingdom	Global Health Trials 2023	Randomised controlled trials addressing any major health related problem affecting LMICs, particularly those that affect the most vulnerable populations. Focus on late-stage (equivalent to phase III/IV) clinical and health intervention trials that evaluate efficacy and effectiveness	Foreign, Commonwealth & Development Office, Medical Research Council	60	TBC		Research & Innovation activity			Advance development and Strengthen scientific use of new or improved excellence technologies	Information exchanged with other GH EDCTP3 Member States in preparation for dialogue on partnership opportunities and to find synergies between GH	€
IKAA2023-3422	United Kingdom	MRC Fellowships 2023	MRC offers a range of fellowship schemes to meet diverse needs allowing training placements in the UK, abroad or in industry. Aimed at supporting a range of career development and capacity strengthening opportunities for scientists at all levels and across the breadth of biomedical research	Medical Research Council	60	TBC		Training activity			Advance development and Strengthen scientific use of new or improved excellence technologies	Information exchanged with other GH EDCTP3 Member States in preparation for dialogue on partnership opportunities and to find synergies between GH	€
IKAA2023-3421	United Kingdom	MRC Research Grants 2023	MRC funds research through a range of grants and highlight notices in response-mode via MRC Research Boards and Panels. The MRC supports research in all major disease areas across the biomedical spectrum, from fundamental lab-based science to early phase clinical trials	Medical Research Council	60	BC		Research & Innovation activity			Advance development and Strengthen scientific use of new or improved excellence technologies	Information exchanged with other GH EDCTP3 Member States in preparation for dialogue on partnership opportunities and to find synergies between GH	€
IKAA2023-3447	United Kingdom	· · · ·	PrEPVacc is a Phase IIb, three-arm, two-stage HIV vaccine efficacy trial with a second randomisation to compare the newer PrEP drug Descovy to the established standard for PrEP, Truvada. The trial aims to recruit 1668 participants from populations at high risk of HIV infection.	Medical Research Council	24	Uganda, South Africa	HIV; vaccines	Research & Innovation activity	Funding subject to formal confirmation and depending on available budget. This IKAA provides supplementary funding to cover COVID-19 related project delays to the EDCTP2 project PrEpVacc (RIA2016V-1644), to enable additional trial staff to be employed at clinical centres in Uganda and South Africa to increase enrolment of participants at these sites.	funding has already been provided by the UK and Germany.	-	Information exchanged with other GH EDCTP3 Member States in preparation for dialogue on partnership opportunities and to find synergies between GH EDCTP3 additional activities.	€
IKAA2023-3448	United Kingdom	Field studies of an oral whole cell ETEC vaccine candidate	This project will conduct a Phase 1/2 descending-age and a Phase 2b efficacy trial of an ETEC vaccine candidate (ETVAX®) in Zambia and The Gambia in African toddlers and children. These two trials and associated microbiology and immunology studies are designed to make ETVAX® ready for a subsequent Phase 3 trial in children in LMIC.	Medical Research Council	36	The Gambia, Zambia	ETEC; vaccines	Research & Innovation activity	Funding subject to formal confirmation and depending on available budget. This IKAA will provide supplementary funding to cover COVID-19 related project delays to the EDCTP2 project ETEC Vaccine Efficacy (RIA2017S		Advance development and Strengthen scientific use of new or improved excellence technologies	Information exchanged with other GH EDCTP3 Member States in preparation for dialogue on partnership opportunities and to find synergies between GH EDCTP3 additional activities.	€
IKAA2023-3449	United Kingdom	PANDORA-ID-NET	Pan-African Network For Rapid Research, Response, Relief and Preparedness for Infectious Diseases Epidemics is a 'ONE HEALTH' multidisciplinary consortium of partners that aims to strengthen regional and pan-African capacities and systems for enabling rapid and effective response to infectious diseases with epidemic potential, arising from within Africa or those imported from overseas.		12	Gabon, Ghana, Nigeria, Sierra Leone, Sudan, Tanzania, Uganda, Zambia	Emerging infections, incl. Ebola, Lassa Fever; COVID- 19; Capacity development		-	Supplementary funding has already been provided by Germany.	Strengthen research and innovation capacity Strengthen scientific excellence	Information exchanged with other GH EDCTP3 Member States in preparation for dialogue on partnership opportunities and to find synergies between GH EDCTP3 additional activities.	€

ID-NET (RIA2016E-1609).

IKAA2023-3424	United Kingdom	Applied Global Health Research 2023	The Applied Global Health Research Board supports applied research that will be of direct and primary benefit to the health of vulnerable populations living in LMICs to develop practical solutions to health challenges. This includes implementation research	Foreign, Commonwealth & Development Office, Medical Research Council	60	TBC		Research & Innovation activity			Advance development and Strengthen scientific use of new or improved excellence technologies	Information exchanged with other GH EDCTP3 Member States in preparation for dialogue on partnership opportunities and to find synergies between GH	
IKAA2023-3423	United Kingdom	Global Health Trials 2023	Randomised controlled trials addressing any major health related problem affecting LMICs, particularly those that affect the most vulnerable populations. Focus on late-stage (equivalent to phase III/IV) clinical and health intervention trials that evaluate efficacy and effectiveness	Foreign, Commonwealth & Development Office, Medical Research Council	60	TBC		Research & Innovation activity			Advance development and Strengthen scientific use of new or improved excellence technologies	Information exchanged with other GH EDCTP3 Member States in preparation for dialogue on partnership opportunities and to find synergies between GH	€
IKAA2023-3422	United Kingdom	MRC Fellowships 2023	MRC offers a range of fellowship schemes to meet diverse needs allowing training placements in the UK, abroad or in industry. Aimed at supporting a range of career development and capacity strengthening opportunities for scientists at all levels and across the breadth of biomedical research	Medical Research Council	60	TBC		Training activity			Advance development and Strengthen scientific use of new or improved excellence technologies	Information exchanged with other GH EDCTP3 Member States in preparation for dialogue on partnership opportunities and to find synergies between GH	€
IKAA2023-3421	United Kingdom	MRC Research Grants 2023	MRC funds research through a range of grants and highlight notices in response-mode via MRC Research Boards and Panels. The MRC supports research in all major disease areas across the biomedical spectrum, from fundamental lab-based science to early phase clinical trials	Medical Research Council	60	BC		Research & Innovation activity			Advance development and Strengthen scientific use of new or improved excellence technologies	Information exchanged with other GH EDCTP3 Member States in preparation for dialogue on partnership opportunities and to find synergies between GH	€
IKAA2023-3447	United Kingdom	· · · ·	PrEPVacc is a Phase IIb, three-arm, two-stage HIV vaccine efficacy trial with a second randomisation to compare the newer PrEP drug Descovy to the established standard for PrEP, Truvada. The trial aims to recruit 1668 participants from populations at high risk of HIV infection.	Medical Research Council	24	Uganda, South Africa	HIV; vaccines	Research & Innovation activity	Funding subject to formal confirmation and depending on available budget. This IKAA provides supplementary funding to cover COVID-19 related project delays to the EDCTP2 project PrEpVacc (RIA2016V-1644), to enable additional trial staff to be employed at clinical centres in Uganda and South Africa to increase enrolment of participants at these sites.	funding has already been provided by the UK and Germany.	-	Information exchanged with other GH EDCTP3 Member States in preparation for dialogue on partnership opportunities and to find synergies between GH EDCTP3 additional activities.	€
IKAA2023-3448	United Kingdom	Field studies of an oral whole cell ETEC vaccine candidate	This project will conduct a Phase 1/2 descending-age and a Phase 2b efficacy trial of an ETEC vaccine candidate (ETVAX®) in Zambia and The Gambia in African toddlers and children. These two trials and associated microbiology and immunology studies are designed to make ETVAX® ready for a subsequent Phase 3 trial in children in LMIC.	Medical Research Council	36	The Gambia, Zambia	ETEC; vaccines	Research & Innovation activity	Funding subject to formal confirmation and depending on available budget. This IKAA will provide supplementary funding to cover COVID-19 related project delays to the EDCTP2 project ETEC Vaccine Efficacy (RIA2017S		Advance development and Strengthen scientific use of new or improved excellence technologies	Information exchanged with other GH EDCTP3 Member States in preparation for dialogue on partnership opportunities and to find synergies between GH EDCTP3 additional activities.	€
IKAA2023-3449	United Kingdom	PANDORA-ID-NET	Pan-African Network For Rapid Research, Response, Relief and Preparedness for Infectious Diseases Epidemics is a 'ONE HEALTH' multidisciplinary consortium of partners that aims to strengthen regional and pan-African capacities and systems for enabling rapid and effective response to infectious diseases with epidemic potential, arising from within Africa or those imported from overseas.		12	Gabon, Ghana, Nigeria, Sierra Leone, Sudan, Tanzania, Uganda, Zambia	Emerging infections, incl. Ebola, Lassa Fever; COVID- 19; Capacity development		-	Supplementary funding has already been provided by Germany.	Strengthen research and innovation capacity Strengthen scientific excellence	Information exchanged with other GH EDCTP3 Member States in preparation for dialogue on partnership opportunities and to find synergies between GH EDCTP3 additional activities.	€

1.160.000

5.800.000

1.160.000

3.480.000

500.000

1.714.302

IKAA2023-3450	United Kingdom	Multi-Stage Malaria Vaccine	This project will develop the first multi-stage vaccine	Medical Research Council	27	Burkina I
		Consortium	designed to target multiple stages of the P. falciparum			Leone, T
			malaria parasite's life-cycle, including the sporozoite,			
			liver, blood and mosquito stages. The aim is to develop			
			vaccines for African infants and children at risk of			
			malaria disease and transmission.			

na Faso, Sierra Malaria; vaccines e, Tanzania

activity

Research & Innovation Funding subject to formal confirmation and depending on available budget. This IKAA will provide supplementary funding to cover COVID-19 related project delays to the EDCTP2 project MMVC (RA2016V-1649), to support activities to determine the efficacy of this very promising combination R21+RH5 vaccine in African children over two years of follow-

Advance development and Strengthen scientific Information exchanged with € use of new or improved excellence technologies

other GH EDCTP3 Member States in preparation for dialogue on partnership opportunities and to find synergies between GH EDCTP3 additional activities.

TOTAL VALUE OF EDCTP PLANNED IKAAs TO BE INITIATED IN YEAR 2023 € 86.621.214

Sum of Estimated commitment(€)	Column Labels	
Row Labels	Coordination & Support activity	Other
Austria	750.000,0€	
Belgium	950.000,0€	
Ethiopia		
France	20.160.000,0 €	520.000,0€
Germany		
Mali		
Mozambique		
Norway		
Portugal		
South Africa		
Spain		
Uganda		
United Kingdom		
Grand Total	21.860.000,0 €	520.000,0€

Research & Innovation activity	Research & Innovation activity
1.800.000,0€	
	200.000,0€
4.203.000,0€	
169.299,3 €	152.416,6 €
300.000,0€	
370.000,0€	
1.697.000,0€	
288.000,0€	1.125.000,0€
	12.674.011,0€
32.128.702,0 €	
40.956.001,3 €	14.151.427,6 €

3 750.000,0 € 2.750.000,0 € 200.000,0 € 200.000,0 € 200.000,0 € 2.000.000,0 € 2.000.000,0 € 2.000.000,0 € 2.000.000,0 € 321.715,8 € 300.000,0 € 100.000,0 € 300.000,0 € 293.785,0 € 1.990.785,0 € 1.413.000,0 € 1.413.000,0 € 2.900.000,0 € 35.028.702,0 € 2.730.000,0 € 6.403.785,0 € 86.621.213,8 €	750.000,0 € 2.750.000,0 € 200.000,0 € 630.000,0 € 3.140.000,0 € 2.000.000,0 € 2.000.000,0 € 2.000.000,0 € 321.715,8 € 100.000,0 € 300.000,0 € 300.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 1.413.000,0 € 1.413.000,0 € 2.900.000,0 € 2.900.000,0 €	750.000,0 € 2.750.000,0 € 200.000,0 € 630.000,0 € 3.140.000,0 € 2.000.000,0 € 2.000.000,0 € 2.000.000,0 € 2.000.000,0 € 321.715,8 € 100.000,0 € 300.000,0 € 1.413.000,0 € 1.413.000,0 € 2.900.000,0 € 35.028.702,0 €	tegic Partnership Building activity	Training activity	Grand Total
2.750.000,0 € 200.000,0 € 630.000,0 € 3.140.000,0 € 2.000.000,0 € 2.000.000,0 € 2.000.000,0 € 321.715,8 € 100.000,0 € 300.000,0 € 300.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 100.000,0 € 1.413.000,0 € 1.413.000,0 € 2.900.000,0 € 35.028.702,0 €	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$			
200.000,0 € $630.000,0 €$ $2.000.000,0 €$ $2.000.000,0 €$ $2.000.000,0 €$ $321.715,8 €$ $100.000,0 €$ $100.000,0 €$ $300.000,0 €$ $300.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $1.413.000,0 €$ $12.674.011,0 €$ $2.900.000,0 €$ $35.028.702,0 €$	200.000,0 € $630.000,0 €$ $2.000.000,0 €$ $2.000.000,0 €$ $2.000.000,0 €$ $321.715,8 €$ $100.000,0 €$ $100.000,0 €$ $300.000,0 €$ $300.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $12674.011,0 €$ $2.900.000,0 €$ $35.028.702,0 €$	200.000,0 € $630.000,0 €$ $2.000.000,0 €$ $2.000.000,0 €$ $2.000.000,0 €$ $321.715,8 €$ $100.000,0 €$ $100.000,0 €$ $300.000,0 €$ $300.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $100.000,0 €$ $12.674.011,0 €$ $2.900.000,0 €$ $35.028.702,0 €$			
$630.000,0 \in$ $3.140.000,0 \in$ $28.653.000,0 \in$ $2.000.000,0 \in$ $2.000.000,0 \in$ $321.715,8 \in$ $100.000,0 \in$ $100.000,0 \in$ $300.000,0 \in$ $300.000,0 \in$ $293.785,0 \in$ $1.990.785,0 \in$ $1.413.000,0 \in$ $1.413.000,0 \in$ $2.900.000,0 \in$ $35.028.702,0 \in$	$630.000,0 \in$ $3.140.000,0 \in$ $28.653.000,0 \in$ $2.000.000,0 \in$ $2.000.000,0 \in$ $321.715,8 \in$ $100.000,0 \in$ $100.000,0 \in$ $300.000,0 \in$ $300.000,0 \in$ $293.785,0 \in$ $1.990.785,0 \in$ $1.413.000,0 \in$ $1.413.000,0 \in$ $2.900.000,0 \in$ $35.028.702,0 \in$	$630.000,0 \in$ $3.140.000,0 \in$ $28.653.000,0 \in$ $2.000.000,0 \in$ $2.000.000,0 \in$ $321.715,8 \in$ $100.000,0 \in$ $100.000,0 \in$ $300.000,0 \in$ $300.000,0 \in$ $293.785,0 \in$ $1.990.785,0 \in$ $1.413.000,0 \in$ $1.413.000,0 \in$ $2.900.000,0 \in$ $35.028.702,0 \in$			
$2.000.000,0 \in$ $2.000.000,0 \in$ $321.715,8 \in$ $100.000,0 \in$ $100.000,0 \in$ $300.000,0 \in$ $70.000,0 \in$ $440.000,0 \in$ $293.785,0 \in$ $1.413.000,0 \in$ $12.674.011,0 \in$ $2.900.000,0 \in$ $35.028.702,0 \in$	$2.000.000,0 \in$ $2.000.000,0 \in$ $321.715,8 \in$ $100.000,0 \in$ $100.000,0 \in$ $300.000,0 \in$ $300.000,0 \in$ $70.000,0 \in$ $440.000,0 \in$ $293.785,0 \in$ $1.413.000,0 \in$ $12.674.011,0 \in$ $2.900.000,0 \in$ $35.028.702,0 \in$	$2.000.000,0 \in$ $2.000.000,0 \in$ $321.715,8 \in$ $100.000,0 \in$ $100.000,0 \in$ $300.000,0 \in$ $300.000,0 \in$ $70.000,0 \in$ $440.000,0 \in$ $293.785,0 \in$ $1.413.000,0 \in$ $12.674.011,0 \in$ $2.900.000,0 \in$ $35.028.702,0 \in$	630.000,0€	3.140.000,0€	
321.715,8 € 100.000,0 € 100.000,0 € 300.000,0 € 70.000,0 € 440.000,0 € 293.785,0 € 1.413.000,0 € 12.674.011,0 € 2.900.000,0 € 35.028.702,0 €	321.715,8 € 100.000,0 € 100.000,0 € 300.000,0 € 70.000,0 € 440.000,0 € 293.785,0 € 1.413.000,0 € 12.674.011,0 € 2.900.000,0 € 35.028.702,0 €	321.715,8 € 100.000,0 € 100.000,0 € 300.000,0 € 300.000,0 € 70.000,0 € 440.000,0 € 293.785,0 € 1.990.785,0 € 1.413.000,0 € 1.413.000,0 € 2.900.000,0 € 35.028.702,0 €			
100.000,0 € 100.000,0 € 300.000,0 € 300.000,0 € 70.000,0 € 440.000,0 € 293.785,0 € 1.990.785,0 € 1.413.000,0 € 1.413.000,0 € 2.900.000,0 € 35.028.702,0 €	100.000,0 € 100.000,0 € 300.000,0 € 300.000,0 € 70.000,0 € 440.000,0 € 293.785,0 € 1.990.785,0 € 1.413.000,0 € 1.413.000,0 € 2.900.000,0 € 35.028.702,0 €	100.000,0 € 100.000,0 € 300.000,0 € 300.000,0 € 70.000,0 € 440.000,0 € 293.785,0 € 1.990.785,0 € 1.413.000,0 € 1.413.000,0 € 2.900.000,0 € 35.028.702,0 €			
300.000,0 € 70.000,0 € 440.000,0 € 293.785,0 € 1.990.785,0 € 1.413.000,0 € 12.674.011,0 € 2.900.000,0 € 35.028.702,0 €	300.000,0 € 70.000,0 € 293.785,0 € 1.990.785,0 € 1.413.000,0 € 12.674.011,0 € 2.900.000,0 € 35.028.702,0 €	300.000,0 € 70.000,0 € 440.000,0 € 293.785,0 € 1.990.785,0 € 1.413.000,0 € 12.674.011,0 € 2.900.000,0 € 300.000,0 €	100.000,0 €		
70.000,0 € 440.000,0 € 293.785,0 € 1.990.785,0 € 1.413.000,0 € 1.413.000,0 € 2.900.000,0 € 35.028.702,0 €	70.000,0 € 440.000,0 € 293.785,0 € 1.990.785,0 € 1.413.000,0 € 1.413.000,0 € 2.900.000,0 € 35.028.702,0 €	70.000,0 € 440.000,0 € 293.785,0 € 1.990.785,0 € 1.413.000,0 € 1.413.000,0 € 2.900.000,0 € 35.028.702,0 €			
293.785,0 € 1.990.785,0 € 1.413.000,0 € 1.413.000,0 € 2.900.000,0 € 35.028.702,0 €	293.785,0 € 1.990.785,0 € 1.413.000,0 € 1.413.000,0 € 2.900.000,0 € 35.028.702,0 €	293.785,0 € 1.990.785,0 € 1.413.000,0 € 1.413.000,0 € 2.900.000,0 € 35.028.702,0 €		70.000,0€	
1.413.000,0 € 12.674.011,0 € 2.900.000,0 € 35.028.702,0 €	1.413.000,0 € 12.674.011,0 € 2.900.000,0 € 35.028.702,0 €	1.413.000,0 € 12.674.011,0 € 2.900.000,0 € 35.028.702,0 €			
12.674.011,0 € 2.900.000,0 € 35.028.702,0 €	12.674.011,0 € 2.900.000,0 € 35.028.702,0 €	12.674.011,0 € 2.900.000,0 € 35.028.702,0 €			
2.900.000,0 € 35.028.702,0 €	2.900.000,0 € 35.028.702,0 €	2.900.000,0 € 35.028.702,0 €			
				2.900.000,0€	
			2.730.000,0 €		